NovaBay Pharmaceuticals, Inc.
NBYAMEXHealthcare
$1.47
$-0.48(-24.62%)
Market Cap$39136127
P/E Ratio—
52W High$99.75
52W Low$1.11
NovaBay Pharmaceuticals, Inc. (NBY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NBY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 1, 2026EPS Actual
$21.23
Est. -$1.00 · +2223.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 1, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NBY reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 1, 2026 | -$1.00 | $21.23 | +2223.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$1.00 | -$4.69 | -369.0% | $-0.00B | $0.00B | -117.4% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.21 | -$0.23 | -9.5% | $0.00B | $0.00B | -82.6% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.21 | -$0.34 | -61.9% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.24 | -$0.61 | -154.2% | — | $0.00B | — |
| ▼ Q2 FY2025 | Apr 1, 2025 | -$0.24 | -$33.22 | -13741.7% | $0.00B | $0.00B | -7.6% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.28 | -$0.60 | -114.3% | $0.00B | $0.00B | -2.4% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -$1.23 | -$1.37 | -11.4% | $0.00B | $0.00B | -23.8% |
Q2 FY2026
Apr 1, 2026Beat
EPS Actual
$21.23
EPS Est.
-$1.00
EPS Surpr.
+2223.0%
Revenue
—
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$4.69
EPS Est.
-$1.00
EPS Surpr.
-369.0%
Revenue
$-0.00B
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.23
EPS Est.
-$0.21
EPS Surpr.
-9.5%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.21
EPS Surpr.
-61.9%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.24
EPS Surpr.
-154.2%
Revenue
—
Q2 FY2025
Apr 1, 2025Miss
EPS Actual
-$33.22
EPS Est.
-$0.24
EPS Surpr.
-13741.7%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.60
EPS Est.
-$0.28
EPS Surpr.
-114.3%
Revenue
$0.00B
Q3 FY2024
Aug 13, 2024Miss
EPS Actual
-$1.37
EPS Est.
-$1.23
EPS Surpr.
-11.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.15 | $0.15 | $0.15 | 1 |
| Q3 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q2 FY2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q1 FY2026 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q4 FY2025 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q3 FY2025 | $-1.05 | $-1.05 | $-1.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 1, 2026 | +2223.0% | $1.49 | $1.59 | +6.71% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -369.0% | $1.50 | $1.35 | -10.00% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -9.5% | $5.35 | $5.30 | -0.93% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -61.9% | $2.95 | $3.02 | +2.37% |
| ▼ Q2 FY2025 | May 15, 2025 | -154.2% | $2.97 | $2.90 | -2.36% |
| ▼ Q2 FY2025 | Apr 1, 2025 | -13741.7% | $2.92 | $2.93 | +0.34% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -114.3% | $3.58 | $3.49 | -2.51% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -11.4% | $2.08 | $2.40 | +15.38% |
Q2 FY2026+6.71%
Report Date
Apr 1, 2026
EPS Beat/Miss
+2223.0%
Price Before
$1.49
Price After
$1.59
Q1 FY2026-10.00%
Report Date
Mar 30, 2026
EPS Beat/Miss
-369.0%
Price Before
$1.50
Price After
$1.35
Q4 FY2025-0.93%
Report Date
Nov 7, 2025
EPS Beat/Miss
-9.5%
Price Before
$5.35
Price After
$5.30
Q3 FY2025+2.37%
Report Date
Aug 14, 2025
EPS Beat/Miss
-61.9%
Price Before
$2.95
Price After
$3.02
Q2 FY2025-2.36%
Report Date
May 15, 2025
EPS Beat/Miss
-154.2%
Price Before
$2.97
Price After
$2.90
Q2 FY2025+0.34%
Report Date
Apr 1, 2025
EPS Beat/Miss
-13741.7%
Price Before
$2.92
Price After
$2.93
Q4 FY2024-2.51%
Report Date
Nov 7, 2024
EPS Beat/Miss
-114.3%
Price Before
$3.58
Price After
$3.49
Q3 FY2024+15.38%
Report Date
Aug 13, 2024
EPS Beat/Miss
-11.4%
Price Before
$2.08
Price After
$2.40
Avg Beat Reaction+6.71%
Avg Miss Reaction+0.33%
Beat Rate1 / 8 quarters
Largest Move+15.38% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NBY ends December
NovaBay Pharmaceuticals, Inc. (NBY) most recently reported earnings on April 1, 2026 for Q2 FY2026, posting EPS of $21.23 — beating the analyst consensus of $-1.00 by +2223.0%. The next NBY earnings date is expected around September 1, 2026.
Each quarter, investors track NBY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NBY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NBY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NBY earnings · 5 questionsNovaBay Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. NBY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NBY historically reports after market close (AMC).
NBY earnings datewhen is NBY earningsNBY next earnings datewhen does NBY report earningsNBY earnings calendar
▸ Source: FMP · NovaBay Pharmaceuticals, Inc. SEC filings · US GAAP · NovaBay Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026